A real-life, single-center, observational study evaluating Clinical and Functional Effects of Fluticasone Furoate/Umeclidinium/Vilanterol-Combined Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease
Latest Information Update: 25 Nov 2021
At a glance
- Drugs Fluticasone furoate/umeclidinium/vilanterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
Most Recent Events
- 25 Nov 2021 New trial record